Ribavirin Bioavailability After Telaprevir Exposure

• Status: Completed
• Trial end date: 2015-02-01
• Target enrollment: 0
• Participant gender: All

Summary

Anemia is more frequent in patients receiving telaprevir with pegylated-interferon/ribavirin than in those receiving pegylated-interferon/ribavirin alone. The objective was to measure the impact of telaprevir on ribavirin bioavailability and to assess the concomitant renal function.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hospices Civils de Lyon
• Treatments: Interferons; Ribavirin

Criteria

Inclusion Criteria:

• Patients with hepatitis C virus infection

• Previous non-response to pegylated-interferon/ribavirin therapy

• Re-treatment with pegylated-interferon/ribavirin and telaprevir

Exclusion Criteria:

• Decompensated liver cirrhosis